Results from VIRAGE Ph 2b Trial of VCN-01 in Metastatic Pancreatic Cancer Published in Nature Medicine

“We are proud to see the peer-reviewed results from the VIRAGE trial published in Nature Medicine and made available to the entire scientific community,” said Manel Cascalló, PhD, General Director of Theriva Biologics S.L. and co-author of the article. “As elaborated in the publication, improved overall survival, progression free survival, and duration of response were observed in metastatic pancreatic cancer patients treated with VCN-01 combined with standard-of-care (SoC) gemcitabine/nab-paclitaxel chemotherapy compared to patients receiving SoC chemotherapy alone. Moreover, the Kaplan-Meier survival analysis and the timing of responses in VCN-01 treated patients suggest an immune mediated mechanism of action for VCN-01 in addition to its stroma degrading effects. We are excited about the potential for VCN-01 in different cancer therapy combinations, and we are extremely grateful to the patients who participated in VIRAGE, their families, our clinical investigators and their teams, and our co-authors for their commitment, dedication and diligence.”

Share:

More News

Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20

“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of

“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence

“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib